drugset / Trial / NCT02440230
Safety of OFS Combined With AI Endocrine Therapy in Chinese Premenopausal Breast Cancer Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
To compare safety of adjuvant OFS combined with anastrozole versus OFS combined with exemestane in Chinese premenopausal hormonal receptor(HR) positive breast cancer patients.
Timeline
- Start
- 2015-05
- Primary completion
- 2021-12
- Completion
- 2021-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anastrozole | Other / unclassified | 1 mg | — |
| Comparator | Exemestane | Small molecule | 25 mg | — |
| Background | Goserelin | Other / unclassified | 3.6 mg | Subcutaneous |